OpenNashEarnings

IDEXX Laboratories (IDXX) · Life Sciences

IDEXX Laboratories Q3 2026 earnings: summary, key numbers & outlook

Results filed 2 Nov 2026 · Quarter ended 30 Sep 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

IDEXX placed over 1,900 inVue Dx analyzers in the quarter and bought AI clinical assistant CoVet, extending its diagnostics-plus-software push in veterinary practices.

IDEXX's growth this quarter was driven by volume, led by the inVue Dx analyzer, which had over 1,900 placements and brings the installed base to nearly 11,000 instruments. The premium instrument base grew 11% globally, and VetLab consumables use rose with new product launches. IDEXX Cancer Dx became a multi-cancer panel. International regions grew faster than the U.S., and imaging installations were strong, led by ImageVue DR50 Plus.

Management is pairing diagnostics with software, adding the CoVet AI clinical assistant to support veterinary team productivity and diagnostics utilization. Next up is the MultiCue Dx point-of-care analyzer, to be showcased at an investor session at VMX in January. The risks are integrating CoVet, acquisition costs that lowered the full-year operating margin outlook, and rapid assay volumes that are falling.

Key numbers

Revenue · GAAP
$1,214 million

an increase of 10% as reported and organic

Diluted EPS · GAAP
$4.01

an increase of 18% as reported and 22% on a comparable basis

Net income · GAAP
$317.1M

Gross margin · GAAP
62.9%

increased 110 basis points as reported

Operating income · GAAP
$402.3M

up 13% as reported

Operating margin · GAAP
33.1%

higher by 100 basis points as reported

Operating cash flow · GAAP
$449.7M

Free cash flow · non-GAAP
$420.8M

Segment or metricValueChange
CAG Diagnostics recurring revenue$967.4Mup 11% as reported and organic
IDEXX VetLab consumables$443.2Mup 14% reported and 15% organic
Reference laboratory diagnostic and consulting services$399.1Mup 10% reported and organic
Rapid assay products$89.1Mup 1% as reported and organic
CAG Diagnostics capital instruments$51.5Mflat
Veterinary software, services and diagnostic imaging systems$97.1Mup 11% reported and 10% organic
Water$58.8Mup 8% as reported and organic
Livestock, Poultry and Dairy$34.8Mup 3% as reported and organic
Where each number comes from
  • Revenue: “The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group”
  • Diluted EPS: “Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis.”
  • Net income: “Net income attributable to stockholders | $317,145 | $274,610 | $934,003 | $811,276”
  • Gross margin: “Gross margin of 62.9% increased 110 basis points as reported and 90 basis points on a comparable basis, supported by strong recurring revenue volume gains”
  • Operating income: “Operating profit and growth (as reported) | $402,348 | $354,846 | 13% | $1,190,500 | $1,044,426 | 14%”
  • Operating margin: “Operating margin was 33.1% for the quarter, higher than the prior year period by 100 basis points as reported and by 60 basis points on a comparable basis.”
  • Operating cash flow: “Net cash provided by operating activities | $449,717 | $402,340 | $1,063,127 | $826,045”
  • Free cash flow: “Free cash flow1 | $420,787 | $371,226 | $977,567 | $730,803”
  • CAG Diagnostics recurring revenue: “CAG Diagnostics recurring revenue: | $967,351 | $873,273 | $94,078 | 10.8% | (0.2)% | — | 11.0%”
  • IDEXX VetLab consumables: “IDEXX VetLab consumables | 443,245 | 387,813 | 55,432 | 14.3% | (0.3)% | — | 14.6%”
  • Reference laboratory diagnostic and consulting services: “Reference laboratory diagnostic and consulting services | 399,079 | 362,725 | 36,354 | 10.0% | (0.2)% | — | 10.2%”
  • Rapid assay products: “Rapid assay products | 89,135 | 88,638 | 497 | 0.6% | (0.2)% | — | 0.7%”
  • CAG Diagnostics capital instruments: “CAG Diagnostics capital – instruments | $51,492 | $51,479 | $13 | — | (0.3)% | — | 0.4%”
  • Veterinary software, services and diagnostic imaging systems: “Veterinary software, services and diagnostic imaging systems: | $97,125 | $87,782 | $9,343 | 10.6% | 0.1% | 0.7% | 9.9%”
  • Water: “Water | $58,836 | $54,297 | $4,539 | 8.4% | 0.6% | — | 7.8%”
  • Livestock, Poultry and Dairy: “LPD | $34,828 | $33,944 | $884 | 2.6% | (0.4)% | — | 3.0%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 2026vs year agovs last quarter
Revenue$1.2B+9.9%−0.2%
Operating income$402.3M+13.4%−5.5%
Net income$317.1M+15.5%−6.3%
Diluted EPS$4.01+17.9%−6.1%
Free cash flow$420.8M+13.4%+30.5%
Gross margin62.9%+1.1 pts−1.1 pts
Operating margin33.1%+1.0 pts−1.9 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenue2026$4,741 million - $4,767 million
Reported operating margin202632.1% - 32.3%
EPS2026$14.96 - $15.16
Capital expenditures2026~$160

Key takeaways

  1. inVue Dx placements expand the premium installed base

    IDEXX placed over 1,900 inVue Dx analyzers, bringing the installed base to nearly 11,000 instruments. Each placed instrument drives later consumables demand, so placements feed the recurring-revenue model.

  2. CoVet acquisition adds AI to the software strategy

    IDEXX acquired CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. It links software workflow to testing demand, though integration is a named risk.

  3. Cancer Dx becomes a multi-cancer panel

    IDEXX Cancer Dx is now a multi-cancer panel, which IDEXX says helps practices detect disease earlier. It widens the use of reference-lab and in-clinic testing.

  4. Volume, not price alone, drives consumables growth

    VetLab consumables grew 14% reported, supported by an 11% larger premium installed base, utilization gains from new launches and net price gains. Rapid assay revenue grew only 1% as price offset lower testing volumes.

  5. International diagnostics outgrows the U.S.

    CAG Diagnostics recurring revenue grew 13% reported and 14% organic internationally against 10% in the U.S. IDEXX says both outpaced sector growth.

Charts

Revenue$1.2B+9.9% y/yQ3 2026
Q4 2024: $954.3M (worked out from the annual figure)Q4 ’24$954.3MQ1 2025: $998.4MQ1 ’25$998.4MQ2 2025: $1.1BQ2 ’25$1.1BQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $1.1B (worked out from the annual figure)Q4 ’25$1.1BQ1 2026: $1.1BQ1 ’26$1.1BQ2 2026: $1.2BQ2 ’26$1.2BQ3 2026: $1.2BQ3 ’26$1.2B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$954.3M *
Q1 2025$998.4M
Q2 2025$1.1B
Q3 2025$1.1B
Q4 2025$1.1B *
Q1 2026$1.1B
Q2 2026$1.2B
Q3 2026$1.2B
Diluted EPS (GAAP)$4.01+17.9% y/yQ3 2026
Q1 2025: $2.96Q1 ’25$2.96Q2 2025: $3.63Q2 ’25$3.63Q3 2025: $3.40Q3 ’25$3.40Q1 2026: $3.47Q1 ’26$3.47Q2 2026: $4.27Q2 ’26$4.27Q3 2026: $4.01Q3 ’26$4.01
Data
Q1 2025$2.96
Q2 2025$3.63
Q3 2025$3.40
Q1 2026$3.47
Q2 2026$4.27
Q3 2026$4.01

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin33.1%+1.0 pts y/yQ3 2026
Q4 2024: 27.4%Q4 ’2427.4%Q1 2025: 31.7%Q1 ’2531.7%Q2 2025: 33.6%Q2 ’2533.6%Q3 2025: 32.1%Q3 ’2532.1%Q4 2025: 28.9%Q4 ’2528.9%Q1 2026: 31.8%Q1 ’2631.8%Q2 2026: 35.0%Q2 ’2635.0%Q3 2026: 33.1%Q3 ’2633.1%
Data
Q4 202427.4%
Q1 202531.7%
Q2 202533.6%
Q3 202532.1%
Q4 202528.9%
Q1 202631.8%
Q2 202635.0%
Q3 202633.1%
Free cash flow$420.8M+13.4% y/yQ3 2026
Q4 2024: $232.8MQ4 ’24$232.8MQ1 2025: $207.9MQ1 ’25$207.9MQ2 2025: $151.6MQ2 ’25$151.6MQ3 2025: $371.2MQ3 ’25$371.2MQ4 2025: $326.3MQ4 ’25$326.3MQ1 2026: $234.3MQ1 ’26$234.3MQ2 2026: $322.5MQ2 ’26$322.5MQ3 2026: $420.8MQ3 ’26$420.8M
Data
Q4 2024$232.8M
Q1 2025$207.9M
Q2 2025$151.6M
Q3 2025$371.2M
Q4 2025$326.3M
Q1 2026$234.3M
Q2 2026$322.5M
Q3 2026$420.8M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What was the main product news at IDEXX this quarter?

IDEXX placed over 1,900 inVue Dx analyzers, taking the installed base to nearly 11,000, and expanded IDEXX Cancer Dx into a multi-cancer panel. It also acquired the CoVet AI clinical assistant.

What is CoVet and why did IDEXX buy it?

CoVet is an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. IDEXX says it creates more value for customers.

Where is demand strongest?

CAG Diagnostics recurring revenue grew 13% reported internationally versus 10% in the U.S. Growth came from same-store volume, new customers, premium instrument installs and innovation benefits.

What are the weak spots in the business?

Rapid assay revenue rose only 1% as price gains offset lower testing volumes, and capital instrument revenue was flat. Livestock, Poultry and Dairy grew 3%.

What is coming next from IDEXX?

IDEXX will present its next point-of-care analyzer, IDEXX MultiCue Dx, at an investor session at VMX on January 18. It also faces CoVet integration, which it cites as a risk.

Documents

SEC filing

Call recording

Call recording on YouTube ↗. Official replay ↗.